Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL258587 | 0.98 | PRSS1 (0.60) | PRSS1PRSS2PRSS3ALDH1A1GAA | |
| SCHEMBL3388760 | 0.84 | NPC1 (0.62) | ALDH1A1GAACES2CES1TP53 | |
| SCHEMBL3414390 | 0.84 | PRSS1 (0.61) | PRSS1PRSS2PRSS3ALDH1A1CES2 | |
| Hydrochloric Acid SCHEMBL6556328 | 0.84 | NPC1 (0.54) | PRSS1PRSS2PRSS3ALDH1A1GAA | |
| Fluoride SCHEMBL27588568 | 0.83 | NPC1 (0.61) | ALDH1A1GAACES2CES1TP53 | |
| Hydrochloric Acid SCHEMBL29506783 | 0.83 | NPC1 (0.61) | ALDH1A1GAACES2CES1TP53 | |
| Ammonia Solution, Strong SCHEMBL9555537 | 0.83 | NPC1 (0.61) | ALDH1A1GAACES2CES1TP53 | |
| SCHEMBL15599678 | 0.82 | MAPK1 (0.50) | ALDH1A1GAACES1MEN1KMT2A | |
| SCHEMBL16089345 | 0.82 | MAPK1 (0.50) | ALDH1A1GAACES1MEN1KMT2A | |
| SCHEMBL9062780 | 0.82 | CES2 (0.66) | ALDH1A1GAACES2CES1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7037915-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060058321-A1 | Fused heterolaryl derivatives | HAYAKAWA MASAHIKO | 2006-03-16 | — | — | US | disclosed |
| US-20050014771-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-6838457-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
| US-20060058321-A1 | Fused heterolaryl derivatives | PIK3CD, PIK3C2A, PIK3R1 | PRSS1 2370/4885PRSS2 3763/4885PRSS3 3555/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
| US-20020151544-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
| US-20050014771-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PRSS1 2209/4885PRSS2 3561/4885PRSS3 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.